Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg with Melphalan and Fludarabine for Allo-SCT
NCT00038831Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2001
- Primary completion
- Mar 2005
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2001; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00038831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038831.